Santarus initiated with "buy"

06/29/06 - Wedbush Morgan Securities

NEW YORK, June 29 (newratings.com) - Analyst Michael Higgins of Wedbush Morgan initiates coverage of Santarus (SNTS) with a "buy" rating. The 12-month target price is set to $12.

In a research note published yesterday, the analyst mentions that the company appears well posited to benefit from the US pharmaceutical heartburn market, which is valued at $8 billion, with its Zegerid capsules. The analyst believes that Zegerid is the most significant advancement in the treatment of heartburn since the launch of Prilosec in the late 1980s. Zegerid’s clinical profile is unparalleled in the head to head trials against other major heartburn drugs, Wedbush Morgan adds.